ARTHURIAN LIFE SCIENCES
Arthurian Life Sciences Ltd was established by Europe’s leading biotech entrepreneur Professor Sir Chris Evans OBE to act as General Partner of the Wales Life Sciences Investment Fund, a £100 million fund and key part of the Welsh Government’s Life Sciences initiative, as outlined by the Minister for Business, Enterprise, Technology and Science Edwina Hart at the BioWales Conference in 2012. The Fund had its first closing with £50 million on 28th February 2013.
ARTHURIAN LIFE SCIENCES
Social Links:
Industry:
Finance Financial Services Venture Capital
Founded:
2012-01-01
Status:
Active
Contact:
+44 (0)20 7290 1050
Email Addresses:
[email protected]
Technology used in webpage:
SPF ASP.NET Ajax Bounce IO
Similar Organizations
Bridges Fund Management
Bridges Fund Management is a specialist fund manager dedicated to sustainable and impact investment.
Global Life Science Ventures
Global Life Science Ventures is a swiss investment fund focusing exclusively on the life sciences sector.
Trind Ventures
Trind Ventures is an early stage tech fund investing in Northern and Central Europe.
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2016-06-20 | Verona Pharma | Arthurian Life Sciences investment in Post-IPO Equity - Verona Pharma | 44.7 M GBP |
| 2016-01-01 | Rutherford Health | Arthurian Life Sciences investment in Seed Round - Rutherford Health | N/A |
| 2015-09-29 | Apitope | Arthurian Life Sciences investment in Series B - Apitope | 12 M EUR |
| 2015-09-01 | CeQur | Arthurian Life Sciences investment in Series C - CeQur | 100 M USD |
| 2015-04-21 | Sphere Medical Holding | Arthurian Life Sciences investment in Post-IPO Equity - Sphere Medical Holding | 13 M GBP |
| 2014-12-01 | Interrad Medical | Arthurian Life Sciences investment in Series E - Interrad Medical | 7.5 M USD |
| 2014-08-19 | MedaPhor | Arthurian Life Sciences investment in Venture Round - MedaPhor | 4.7 M GBP |
| 2013-07-22 | ReNeuron Group | Arthurian Life Sciences investment in Post-IPO Equity - ReNeuron Group | 25.35 M GBP |